Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K MacAlpine
A Phase I Study of Tipifarnib Combined With Conventional Induction and Consolidation Therapy for Previously Untreated Patients With Acute Myeloid Leukemia Aged 60 Years and Over
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Intensive Consolidation With G-CSF Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy in Acute Myeloid Leukemia Patients ≥60 Years
American Journal of Hematology
Hematology
Phase II Trial of Clofarabine and Daunorubicin as Induction Therapy for Acute Myeloid Leukemia Patients Greater Than or Equal to 60 Years of Age
Leukemia Research
Cancer Research
Oncology
Hematology
A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients <= 60 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Renal Replacement Therapy in Patients Aged Over 60 Years.
Postgraduate Medical Journal
Medicine
Idarubicin, Cytarabine and Pravastatin as Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 With Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
